This cluster groups 2 independently calculated changes: Cash & equivalents increased 35.1%; Operating cash flow increased 51.8%.
2 evidence-backed components· Pharmaceutical Preparations
RESEARCH SNAPSHOTAlzamend Neuro, Inc.'s latest supported as-filed period reports net income of -$3.0M, 111.6% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents increased 35.1%; Operating cash flow increased 51.8%.
2 evidence-backed componentsOperating income changed -111.8% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
ALZN · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001214659-26-011572SEC ↗4Aug 31, 2026Period Aug 26, 20260001214659-26-011121SEC ↗4/AAug 31, 2026Period Apr 14, 20260001214659-26-011111SEC ↗4/AAug 31, 2026Period Apr 14, 20260001214659-26-011110SEC ↗4Aug 4, 2026Period Jul 31, 20260001214659-26-009594SEC ↗8-KAug 3, 2026Period Aug 3, 20260001214659-26-009469SEC ↗10-KJul 22, 2026Period Apr 30, 20260001214659-26-008832SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 26, 2026Filed Aug 31, 2026 | AULT MILTON C IIIDirector | Open Market SaleDirect | 2,000 | $2 | $3,116 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Net income changed -111.6% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Operating cash flow changed +51.8% from the comparable as-filed period.
Research & development changed +186.0% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Shares outstanding changed +53.7% from the comparable as-filed period. The change ranks at the 62th percentile of 8 prior comparable changes.
Research & development changed -37.6% from the comparable as-filed period.
Cash & equivalents changed +35.1% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-07-31. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001214659-26-008772